No Data
No Data
REGENXBIO Releases New Data on DMD Drug Ahead of Earnings
AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program Into the Clinic
PepGen Stock Tumbles 25% Following Release of DMD Drug Data
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Express News | Dyne Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating on the Stock and Raised Its Price Target From $39 to $43